2323

Splicing Factor Activity for Diagnosing and Treating Cancer

Karni Rotem, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology

Splicing factor levels predict patient prognosis and its inhibition blocks invasive cancers

Categories

Oncology/Cancer, RNA/Protein/Diagnosis, Biomarkers

Clinical Data

Between 20-80 human samples on each biomarker

Therapeutic in-vivo POC

Patent Status

Patent filed in the United States

Market

Cancer testing is currently one of the most important growth opportunities diagnostics segment. The worldwide market for in vitro cancer diagnosis is estimated in few billions.

Highlights

  • Detection of the levels of a specific splicing factors used to indicate presence of cancer and cancer outcome.
  • Successfully demonstrated ability to predict the survival time of patients with brain tumors and to detect the metastatic stages of breast cancer
  • Down-regulation of specific a splicing factors inhibits glioblastoma development and metastasis of breast cell into the lungs in mouse xenograft models
  • Splicing factor levels are better prognostic markers than markers currently in use.
  • Highly sensitive diagnostic tool
  • New treatment approach

Our Innovation

Novel approach to diagnosing cancer and a patient's sensitivity to specific drugs using the levels in the body of certain splicing factors as markers; local down-regulation of splicing factors by Antisense RNA oligos for the treatment of glioblastoma and metastatic breast cancer

 

Key Features

  • Novel cancer biomarkers were identified
  • nnRNP A2/B1 was shown to be powerful diagnostic and prognostic marker for glioblastoma and various metastasis stages of breast cancer
  • New Efficient treatment for glioblastoma and metastatic breast cancer

Development Milestones

Seeking funding for ongoing research, further animal trials, and accumulation of patient data

The Opportunity

Applications in cancer diagnosis and  a new treatment for glioblastoma and metastatic breast cancer

Patent Status

Granted US 9,187,787

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
+972-2-6586692
Contact ME:
Image CAPTCHA